FDA Advisory Panel Opens Two-Day Review Of Seven Unapproved Peptide Therapies
11h
Developing
5
An FDA advisory committee opened a two-day meeting on July 23 in Washington, D.C., to decide whether compounding pharmacies should be allowed to make seven popular unapproved peptide therapies. PBS
